Fundraising Fox
K2 Biolabs
Houston, US · Founded 2021 · Delaware corporation · 15 employees on LinkedIn · 1 known investors
Find your way into K2 Biolabs
Sign up to see every warm intro you have to K2 Biolabs
- Paths you didn't know you had: your email and LinkedIn already hold routes to the K2 Biolabs team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
K2bio operates a fully equipped, AAALAC-accredited contract vivarium facility in Houston supporting preclinical research for biotechnology and pharmaceutical companies. The facility provides flexible access to animal housing, technical services, imaging systems, and expertise across multiple therapeutic modalities including biologics, small molecules, and cell therapies.
Founders & leadership
KJ
Kieron JonesCo-Founder & CEO2021–2023Kieron Jones has held roles in defense contracting, construction, and life sciences sectors. He currently serves as CEO and Board Member of K2 Biolabs, a contract research organization operating a vivarium facility in Houston.
Board
KS
AD
Andrew DeSommaMember of the Board of Directors
GF
Gerard FleuryMember of the Board of Directors
CJ
Clifford J. StocksMember of the Board of Directors
AS
Andrew StrongCo-Founder and Board Chair
Investors · 1
Reported raises · per SEC filings
Form D private placements$6.1M disclosed across 2 rounds · 2021–2023
▶$615.5KraisedAug 2023 · 7 investors · BiotechnologyRule 506(b)
▶$615.5KraisedAug 2023 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Andrew DeSommaDirector
- Gerard FleuryDirector
- Clifford J. StocksDirector
- Andrew StrongDirector
- Daniel ClarkExecutive Officer
- Kevin SlawinDirector
- Kieron JonesDirector, Executive Officer
- Offering amount
- $3M
- Amount sold
- $615.5K
- First sale
- Jun 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$5.5MraisedMar 2021 · 40 investors · BiotechnologyRule 506(b)
▶$5.5MraisedMar 2021 · 40 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- KIERON JONESExecutive Officer, Director
- Andrew StrongDirector
- Andrew DeSommaDirector
- Kevin SlawinDirector
- Clifford StocksDirector
- Offering amount
- $5.5M
- Amount sold
- $5.5M
- Minimum investment
- $25K
- Proceeds to insiders
- $270K
- First sale
- Mar 2021
- Incorporated
- Limited Liability Company, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 5
bioBIO is the world's largest advocacy association representing biotechnology companies and research institutions across the United States and 30+ other nations. The organization facilitates industry networking through events, conferences, and partnering software while providing cost-savings programs and advocacy services for member companies.
KALA BIOA biopharmaceutical company developing an artificial intelligence infrastructure platform designed for on-premises deployment in biotechnology and pharmaceutical research environments, serving biotech firms and pharma companies seeking secure access to advanced AI capabilities while retaining control over proprietary biological data; the company is also evaluating strategic alternatives for its legacy mesenchymal stem cell secretome assets after discontinuing its lead rare eye disease therapeutic program.
Krystal BiotechKrystal Biotech discovers, develops, and commercializes genetic medicines, including gene therapy programs for rare diseases such as dermatological conditions. The company operates across the US, Europe, and Japan.
Coya TherapeuticsCoya Therapeutics is a clinical-stage biotechnology company developing regulatory T cell (Treg) therapeutic modalities to treat neurodegenerative, autoimmune, and metabolic diseases. Its programs include the ALSTARS clinical trial in ALS.
Korro BioKorro Bio is a biotechnology company developing a new class of RNA-editing therapies guided by human genetics and disease biology. It aims to create genetic medicines for patients with rare and highly prevalent debilitating or life-threatening diseases.
Companies working in the same space as K2 Biolabs.
Frequently asked questions
- What does K2 Biolabs do?
- K2bio operates a fully equipped, AAALAC-accredited contract vivarium facility in Houston supporting preclinical research for biotechnology and pharmaceutical companies. The facility provides flexible access to animal housing, technical services, imaging systems, and expertise across multiple therapeutic modalities including biologics, small molecules, and cell therapies.
- Who are K2 Biolabs's investors?
- K2 Biolabs's investors include Rapha Capital Management, LLC.
- How much funding has K2 Biolabs raised?
- K2 Biolabs has disclosed $6.1M raised across 2 rounds.
- Where is K2 Biolabs headquartered?
- K2 Biolabs is headquartered in Houston, US.